Unknown

Dataset Information

0

Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.


ABSTRACT: Human factor Xa (FXa) is a serine protease of the common coagulation pathway. FXa is known to activate prothrombin to thrombin, which eventually leads to the formation of cross-linked blood clots. While this process is important in maintaining hemostasis, excessive thrombin generation results in a host of thrombotic conditions. FXa has also been linked to inflammation via protease-activated receptors. Together, coagulopathy and inflammation have been implicated in the pathogenesis of viral infections, including the current coronavirus pandemic. Direct FXa inhibitors have been shown to possess anti-inflammatory and antiviral effects, in addition to their established anticoagulant activity. This review summarizes the pharmacological activities of direct FXa inhibitors, their pharmacokinetics, potential drug-drug interactions and adverse effects, and the details of clinical trials involving direct FXa inhibitors in coronavirus disease 2019 (COVID-19) patients.

SUBMITTER: Al-Horani RA 

PROVIDER: S-EPMC7486161 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5597622 | biostudies-literature
| S-EPMC3408863 | biostudies-literature
| S-EPMC2714770 | biostudies-literature
| S-EPMC7845056 | biostudies-literature
| S-EPMC9036856 | biostudies-literature
| S-EPMC6273828 | biostudies-literature
| S-EPMC8733676 | biostudies-literature
| S-EPMC9343596 | biostudies-literature
| S-EPMC5965044 | biostudies-literature
| S-EPMC11251598 | biostudies-literature